Does UnitedHealthcare Cover Ozempic?

UnitedHealthcare Formulary Placement for Ozempic

Ozempic sits on Tier 3 (preferred brand) of the standard UnitedHealthcare commercial formulary for both PPO and HMO plans. Tier 3 copays typically range from $40 to $75 per fill, though the exact amount depends on the specific plan document. Employer-sponsored plans may modify this placement.

Semaglutide earned its formulary position based on the SUSTAIN clinical trial program, which demonstrated consistent A1C reductions of 1.2% to 1.8% across doses and comparators [1]. The FDA approved Ozempic in December 2017 as an adjunct to diet and exercise for adults with type 2 diabetes [2]. UnitedHealthcare's pharmacy and therapeutics committee reviews formulary placement annually, weighing clinical outcomes data from trials like SUSTAIN-7 against cost-effectiveness benchmarks [3].

Plans purchased through UnitedHealthcare's individual marketplace exchange may use a different formulary. Members should verify their specific tier by logging into myuhc.com or calling the number on the back of their insurance card. The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as second-line therapy for patients with established atherosclerotic cardiovascular disease or high cardiovascular risk, which strengthens the clinical rationale for coverage [4].

Prior Authorization Requirements

UnitedHealthcare requires prior authorization for Ozempic on all commercial plans. The PA process is rated moderate difficulty. Approval hinges on three core criteria: a confirmed type 2 diabetes diagnosis (ICD-10 E11.x), documentation that A1C remains above the individualized target on current therapy, and evidence that the patient has tried and failed (or has a contraindication to) at least one preferred formulary alternative.

The prescriber submits the PA request through the UnitedHealthcare pharmacy portal or by fax. Turnaround for standard requests is 72 hours; urgent requests are processed within 24 hours per federal parity requirements. Documentation should include recent lab values (A1C within the past 90 days), current medication list, and a brief clinical rationale [5].

The Endocrine Society's 2024 clinical practice guideline recommends GLP-1 receptor agonists for patients with type 2 diabetes and a BMI of 27 or above, supporting prior authorization approval in that population [6]. A1C thresholds that most UnitedHealthcare plans require for approval typically fall at 7.0% or above after 90 days on metformin, though some employer-customized plans set stricter or more lenient cutoffs. The ADA recommends individualized A1C targets, which prescribers can cite when the plan's rigid threshold does not match the patient's clinical picture [7].

Step Therapy: What You Must Try First

Most UnitedHealthcare commercial plans enforce step therapy before approving Ozempic. The standard step requires a documented 90-day trial of metformin at a dose of at least 1 to 500 mg daily (or maximum tolerated dose), with lab evidence that A1C remains above the individualized goal.

Some plans also accept a sulfonylurea or an SGLT2 inhibitor as a qualifying step-therapy agent. The American Association of Clinical Endocrinology (AACE) consensus algorithm positions GLP-1 receptor agonists ahead of sulfonylureas in the treatment hierarchy for patients with cardiovascular risk factors, giving prescribers a guideline-backed argument to request a step-therapy override [8].

Patients with documented metformin intolerance (GI side effects at doses below 1 to 500 mg) or contraindications (eGFR <30 mL/min) can request a step-therapy exception. The prescriber should include pharmacy records showing the metformin fill and discontinuation date, plus a clinical note explaining the reason for intolerance. A Cochrane review on metformin tolerability found that up to 25% of patients experience GI side effects significant enough to limit dose titration, a statistic worth citing in exception requests [9].

Off-Label Coverage for Weight Loss

UnitedHealthcare commercial plans generally do not cover Ozempic for weight management alone. Ozempic's FDA-approved indication is type 2 diabetes, not obesity. Novo Nordisk markets a separate semaglutide product, Wegovy (2.4 mg weekly), specifically for chronic weight management [10].

Some employer-sponsored UnitedHealthcare plans have added obesity pharmacotherapy riders since 2024, and a small number of those riders include Ozempic off-label. Members should check their Summary of Benefits and Coverage (SBC) for "anti-obesity medication" or "weight management drug" language. Without that rider, submitting Ozempic with an obesity-only diagnosis (ICD-10 E66.01) will result in a denial.

The Treat and Reduce Obesity Act, if passed, would expand Medicare Part D coverage of FDA-approved anti-obesity medications, but it does not directly affect UnitedHealthcare commercial policy. For patients who carry both a type 2 diabetes and an obesity diagnosis, the prescriber should submit the PA under the diabetes indication. The NIH clinical guidelines on obesity define pharmacotherapy eligibility at BMI 30 or above (or 27 with comorbidities), which can support medical necessity arguments for dual-diagnosis patients [11].

How to Appeal a UnitedHealthcare Ozempic Denial

UnitedHealthcare offers a two-level internal appeal process, followed by an external independent review organization (IRO) review. Most denials for Ozempic fall into two categories: missing step-therapy documentation or insufficient clinical rationale.

First-level internal appeal. The member or prescriber has 180 days from the denial date to file. Submit the appeal letter with updated labs, medication history, and a letter of medical necessity from the prescribing physician. Reference the ADA Standards of Care or AACE algorithm to counter clinical objections [12]. UnitedHealthcare must respond within 30 days for standard appeals or 72 hours for urgent (expedited) appeals.

Second-level internal appeal. If the first appeal is denied, members can escalate within 60 days. Different reviewers evaluate the case. Include any new clinical evidence, such as an endocrinologist's letter or additional trial data. Citing the cardiovascular benefit data from the SUSTAIN-6 trial (N=3,297; 26% reduction in major adverse cardiovascular events with semaglutide vs. placebo) strengthens the argument for patients with ASCVD risk [13].

External IRO review. After exhausting both internal levels, the member can request an external review through the state insurance department. The IRO is an independent physician panel that evaluates whether the denial was clinically appropriate. This right is guaranteed under the Affordable Care Act's external review provisions [14]. The external review decision is binding on UnitedHealthcare.

A peer-to-peer call between the prescriber and UnitedHealthcare's medical director can sometimes resolve denials faster than the formal appeal process. Request this within the first-level appeal window.

Manufacturer Savings Card and Copay Assistance

Novo Nordisk offers the Ozempic Savings Card, which can reduce out-of-pocket costs to as low as $25 per 1-month or 3-month prescription fill for commercially insured patients. The card covers up to $150 per fill for the first 24 months. It cannot be combined with Medicare, Medicaid, or other federal healthcare programs.

For UnitedHealthcare members with high Tier 3 copays, the savings card effectively bridges the gap between the plan's cost-sharing amount and what the patient actually pays at the pharmacy. Patients should present both their UnitedHealthcare insurance card and the Ozempic Savings Card at the pharmacy counter. The FDA's information page on semaglutide confirms the approved dosing (0.25 mg, 0.5 mg, 1 mg, and 2 mg pens), which is relevant because the savings card applies per prescription, regardless of dose [15].

Patients who do not qualify for the savings card (Medicare Part D enrollees, for example) can explore Novo Nordisk's Patient Assistance Program (PAP), which provides Ozempic at no cost to uninsured or underinsured individuals meeting income criteria (typically at or below 400% of the federal poverty level).

Clinical Evidence Supporting Ozempic Coverage

UnitedHealthcare's coverage of Ozempic reflects a body of evidence across the SUSTAIN trial program. SUSTAIN-7 (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks. Semaglutide 1.0 mg reduced A1C by 1.8% versus 1.4% with dulaglutide 1.5 mg (P<0.0001) [3].

SUSTAIN-6 (N=3,297) demonstrated that semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared with placebo over a median follow-up of 2.1 years (HR 0.74 to 95% CI 0.58 to 0.95, P=0.02) [13]. This cardiovascular outcome trial was a key factor in the ADA's recommendation of GLP-1 RAs as preferred second-line therapy for patients with established ASCVD [16].

Weight loss is a secondary benefit. In SUSTAIN-7, patients on semaglutide 1.0 mg lost a mean 6.5 kg versus 3.0 kg with dulaglutide 1.5 mg. Dr. Richard Pratley, lead author of SUSTAIN-7, noted: "The magnitude of A1C reduction and weight loss with semaglutide exceeded that of dulaglutide at both dose comparisons" [3].

The SELECT trial (N=17,604) later showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, even without diabetes [17]. While SELECT studied the higher Wegovy dose, UnitedHealthcare medical directors may reference this data when evaluating cardiovascular benefit arguments for Ozempic.

Dosing, Titration, and Plan Quantity Limits

Ozempic is administered as a once-weekly subcutaneous injection. The FDA-approved titration schedule starts at 0.25 mg weekly for 4 weeks (initiation dose, not for glycemic control), then increases to 0.5 mg weekly [2]. After at least 4 weeks on 0.5 mg, the dose can increase to 1.0 mg if additional glycemic control is needed. A 2.0 mg dose option is available for patients who need further A1C reduction after at least 4 weeks on 1.0 mg.

UnitedHealthcare typically authorizes a quantity limit of one pen per 28 days for the 0.5 mg and 1.0 mg strengths. The 2.0 mg pen is also limited to one per 28 days. Requests for early refills or overlapping fills will be rejected at the pharmacy level. If a dose change occurs mid-cycle, the prescriber may need to submit a new PA to align the quantity limit with the new dose.

The Endocrine Society advises maintaining patients on the lowest effective dose that achieves A1C targets, which supports keeping patients at 0.5 mg or 1.0 mg rather than automatically titrating to maximum [6]. This approach also avoids potential coverage complications if the plan requires re-authorization at higher doses.